Akebia Therapeutics (AKBA) EBT Margin (2017 - 2026)

Akebia Therapeutics (AKBA) has 10 years of EBT Margin data on file, last reported at 16.67% in Q1 2026.

• EBT Margin for Q1 2026 came in at 16.67%, down 2733.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.07% (up 1643.0% YoY), and the FY2025 annual result was 1.58%, up 4176.0% from the prior year.
• EBT Margin climbed to 16.67% in Q1 2026 per AKBA's latest filing, from 19.5% in the prior quarter.
• Over five years, EBT Margin peaked at 67.05% in Q2 2022 and troughed at 156.25% in Q1 2022.
• A 5-year average of 31.37% and a median of 19.66% in 2024 frame the typical range for EBT Margin.
• The sharpest annual moves came in 2022 and 2023: EBT Margin soared 22637 bps in 2022, then sank 8687 bps in 2023.
• A 5-year view of EBT Margin shows it stood at 11.66% in 2022, then surged by 109 bps to 1.09% in 2023, then tumbled by 4589 bps to 49.04% in 2024, then surged by 60 bps to 19.5% in 2025, then advanced by 14 bps to 16.67% in 2026.
• Business Quant data shows AKBA's EBT Margin at 16.67% in Q1 2026, 19.5% in Q4 2025, and 1.97% in Q3 2025.